866-997-4948(US-Canada Toll Free)

Men`s Health Therapeutics Market to 2017 - Availability of Generic Sildenafil from 2012 to Restrain Market Growth

Published By :

GBI Research

Published Date : Jan 2012

Category :

Therapeutic Area

No. of Pages : 130 Pages



GBI Research, the leading business intelligence provider, has released its latest research “Men's Health Therapeutics Market to 2017 - Availability of Generic Sildenafil from 2012 to Restrain Market Growth”. The report provides in-depth analysis of drivers and barriers that impact the global men’s health therapeutics market. The report analyzes the markets for men’s health in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, market revenue, and the annual cost of treatment (ACT) are forecast until 2017 for the key geographies, as well as the leading therapeutic segments. Furthermore, the report provides profiles of the leading companies, and analyzes the mergers and acquisitions (M&As) and licensing agreements that shape the global markets. 

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

GBI Research finds that the men’s health therapeutics market will continue to grow only moderately. The principal reason for this stagnancy will be the first patent expiry of a top selling blockbuster, Viagra. The overall men’s health market is driven by the launch of late-stage pipeline candidates and the steady increase in the diseased and treated population. The erectile dysfunction (ED) and benign prostatic hyperplasia (BPH) markets constitute a major portion of the men’s health market. In 2010, these markets accounted for more than 80% of the total men’s health therapeutics market. Male hypogonadism accounted for 8.6% of the total market size. The premature ejaculation market represents a small portion of the total men’s health market. The premature ejaculation market does not have any FDA approved products in the major market geographies. However, it will grow at a higher rate during the forecast period compared to the erectile dysfunction and male hypogonadism market. This is because the premature ejaculation market will see the launch of promising new drugs in the future. In 2009, the global men’s health therapeutics market was estimated to be worth $9,162m. GBI Research forecasts the market to grow at a compound annual growth rate (CAGR) of approximately 4.1% between 2010 and 2017 to record a sales value of approximately $12,163m by 2017. 

The men’s health market has a moderate level of unmet needs. The current treatment options in the erectile dysfunction and male hypogonadism market are efficacious and have a manageable safety profile with the exception of some rare but serious side effects. The unmet need in the premature ejaculation market is huge. This is because the market lacks any FDA approved products for treatment of the disease in major geographies. There exists an opportunity for pharmaceutical companies to produce drugs with improved efficacy, improved patient compliance and competitive pricing in the future. The men’s health pipeline does contain few potential drugs which will help sustain market growth in the forecast period. However, the men’s health Research and Development (R&D) pipeline is not very innovative, with most of the projects in the late stage pipeline being me-too products.

Scope

  • Annualized market data for the men’s health therapeutics market from 2002 to 2010 and forecast to 2017.
  • Analysis of the leading therapeutic segments, including erectile dysfunction, male hypogonadism, premature ejaculation and benign prostatic hyperplasia.
  • Analysis of the men’s health therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan.
  • Market characterization of the men’s health therapeutics market, including market size, revenue analysis by top seven geographies, generic share, annual cost of treatment, a treatment flow algorithm and treatment usage patterns.
  • Key drivers and restraints that have a significant impact on the market.
  • Coverage of pipeline molecules in various phases of drug development.
  • Competitive benchmarking of leading companies. The key companies studied in this report are Pfizer Inc., Eli Lilly and Company, GlaxoSmithKline Inc., Bayer Healthcare AG, Abbott Laboratories, Endo Pharmaceuticals Holding Inc., Johnson and Johnson, VIVUS Inc. and Auxilium Pharmaceuticals, Inc.
  • Key M&A activities and licensing agreements, that have taken place in the period 2004-2011 in the global men’s health therapeutics market.
Reasons to buy

  • Align your product portfolio to the markets with the highest growth potential.
  • Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.
  • Develop key strategic initiatives by understanding the key focus areas of leading companies.
Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Men’s Health Therapeutics Market to 2017 - Introduction
2.1 Overview
2.2 GBI Research Report Guidance

3 Men’s Health Therapeutics Market to 2017 - Market Characterization
3.1 Overview
3.2 Market Forecasts
3.3 Global Generic/Off-label Share
3.4 Annual Cost of Treatment
3.5 Treatment Usage Patterns
3.5.1 Diseased Population
3.5.2 Treatment Seeking Population
3.5.3 Diagnosed Population
3.5.4 Treated Population
3.5.5 Drivers and Restraints of the Men’s Health Therapeutics Market

4 Men’s Health Therapeutics Market To 2017 - Geographical Landscape
4.1 Market Forecasts by Country
4.2 The US
4.2.1 Market Forecasts
4.2.2 Annual Cost of Treatment
4.2.3 Treatment Usage Patterns
4.3 Top Five Countries in Europe
4.3.1 Market Forecasts
4.3.2 Annual Cost of Treatment
4.3.3 Treatment Usage Patterns
4.4 Japan
4.4.1 Market Forecasts
4.4.2 Annual Cost of Treatment
4.4.3 Treatment Usage Patterns

5 Men’s Health Therapeutics Market to 2017 - Therapeutic Landscape
5.1 Global Erectile Dysfunction (ED) Therapeutics Market
5.1.1 Market Overview
5.1.2 Market Forecasts
5.1.3 Revenue Analysis by Country
5.1.4 Global Generic/Off-Label Share
5.1.5 Annual Cost of Treatment
5.1.6 Treatment Flow Algorithm
5.1.7 Treatment Usage Patterns
5.1.8 Product Analysis
5.1.9 Drivers and Restraints of the ED Therapeutics Market
5.2 Global Male Hypogonadism Therapeutics Market
5.2.1 Market Overview
5.2.2 Market Forecasts
5.2.3 Revenue Analysis by Country
5.2.4 Global Generic/Off-label Share
5.2.5 Annual Cost of Treatment
5.2.6 Treatment Flow Algorithm
5.2.7 Treatment Usage Patterns
5.2.8 Product Analysis
5.2.9 Drivers and Restraints of the Male Hypogonadism Therapeutics Market
5.3 Global Premature Ejaculation (PE) Therapeutics Market
5.3.1 Market Overview
5.3.2 Market Forecasts
5.3.3 Revenue by Country
5.3.4 Global Generic/Off-Label Share
5.3.5 Annual Cost of Treatment
5.3.6 Treatment Flow Algorithm
5.3.7 Treatment Usage Patterns
5.3.8 Product Analysis
5.3.9 Drivers and Restraints of the PE Therapeutics Market
5.4 Global Benign Prostatic Hyperplasia (BPH) Market
5.4.1 Overview
5.4.2 Market Forecasts
5.4.3 Revenue Analysis by Country
5.4.4 Generics/Off-Label Share
5.4.5 Annual Cost of Treatment
5.4.6 Treatment Flow Algorithm
5.4.7 Treatment Usage Patterns
5.4.8 Product Analysis
5.4.9 Drivers and Restraints of the BPH Therapeutics Market

6 Men’s Health Therapeutics Market to 2017 - Pipeline Analysis
6.1 Overview
6.2 Research and Development Pipeline by Indication
6.3 Research and Development by Phase of Development
6.4 Research and Development Pipeline - Erectile Dysfunction
6.4.1 Pipeline by Clinical Phases of Development
6.4.2 Profiles of Key Late-Stage Drugs in the Erectile Dysfunction Market
6.5 Research and Development Pipeline - Premature Ejaculation
6.5.1 Pipeline by Clinical Phases of Development
6.5.2 Profiles of Key Late-Stage Drugs in the Premature Ejaculation Market
6.6 Research and Development Pipeline - Male Hypogonadism
6.6.1 Pipeline by Clinical Phases of Development
6.6.2 Profiles of Key Late-Stage Drugs in the Male Hypogonadism Market
6.7 Research and Development Pipeline - Benign Prostatic Hyperplasia
6.7.1 Pipeline by Clinical Phases of Development
6.7.2 Profiles of Key Late-Stage Drugs in the Benign Prostatic Hyperplasia Market

7 Men’s Health Therapeutics Market to 2017 - Competitive Landscape
7.1 Overview
7.2 Company Profiles
7.2.1 Pfizer Inc.
7.2.2 Eli Lilly and Company
7.2.3 GlaxoSmithKline, Inc
7.2.4 Abbott Laboratories
7.2.5 Endo Pharmaceuticals Holding Inc.
7.2.6 Bayer Healthcare AG
7.2.7 Johnson & Johnson
7.2.8 VIVUS, Inc.
7.2.9 Auxilium Pharmaceuticals, Inc.

8 Men’s Health Therapeutics Market to 2017 - Strategic Consolidations
8.1 Overview
8.2 Mergers and Acquisitions
8.2.1 Overview
8.2.2 Major M&A Deals
8.3 Licensing Agreements
8.3.1 Deals by Geography
8.3.2 Deals by Value
8.3.3 Deals by Year
8.4 Major Licensing Agreements
8.5 Co-Development Deals
8.5.1 Major Co-Development Deals

9 Men’s Health Therapeutics Market to 2017 - Appendix
9.1 Market Definitions
9.2 Abbreviations
9.3 Research Methodology
9.3.1 Coverage
9.3.2 Secondary Research
9.3.3 Primary Research
9.3.4 Therapeutic Landscape
9.3.5 Epidemiology-based Forecasting
9.3.6 Market Size by Geography
9.3.7 Geographical Landscape
9.3.8 Pipeline Analysis
9.3.9 Competitive Landscape
9.3.10 Expert Panel Validation
9.4 Contact Us
9.5 Disclaimer
9.6 Sources

List of Table


Table 1: Men’s Health Therapeutics Market to 2017, Global, Revenue, $m, 2002-2010
Table 2: Men’s Health Therapeutics Market to 2017, Global, Revenue Forecasts ,$m, 2010-2017
Table 3: Men’s Health Therapeutics Market to 2017, Global, Annual Cost of Treatment, $, 2002-2010
Table 4: Men’s Health Therapeutics Market to 2017, Global, Annual Cost of Treatment ,$, 2010-2017
Table 5: Men’s Health Therapeutics Market to 2017, Global, Treatment Usage Patterns, million, 2002-2010
Table 6: Men’s Health Therapeutics Market to 2017, Global, Treatment Usage Patterns, million, 2010-2017
Table 7: Men’s Health Therapeutics Market to 2017, Global, Revenue Analysis by Country, $m, 2002-2010
Table 8: Men’s Health Therapeutics Market to 2017, Global, Revenue Analysis by Country, $m, 2010-2017
Table 9: Men’s Health Therapeutics Market to 2017, The US, Revenue, $m, 2002-2010
Table 10: Men’s Health Therapeutics Market to 2017, The US, Revenue Forecasts ,$m, 2010-2017
Table 11: Men’s Health Therapeutics Market to 2017, The US, Annual Cost of Treatment, $, 2002-2010
Table 12: Men’s Health Therapeutics Market to 2017, The US, Annual Cost of Treatment, $, 2010-2017
Table 13: Men’s Health Therapeutics Market to 2017, The US, Treatment Usage Patterns, million, 2002-2010
Table 14: Men’s Health Therapeutics Market to 2017, The US, Treatment Usage Patterns, million, 2010-2017
Table 15: Men’s Health Therapeutics Market to 2017, Top Five Countries of Europe, Revenue, $m, 2002-2010
Table 16: Men’s Health Therapeutics Market to 2017, Top Five Countries of Europe, Revenue Forecasts, $m, 2010-2017
Table 17: Men’s Health Therapeutics Market to 2017, Top Five Countries of Europe, Revenue Analysis by Country, $m, 2002-2010
Table 18: Men’s Health Therapeutics Market to 2017, Top Five Countries of Europe, Revenue Analysis by Country, $m, 2010-2017
Table 19: Men’s Health Therapeutics Market to 2017, Top Five Countries of Europe, Annual Cost of Treatment, $, 2002-2010
Table 20: Men’s Health Therapeutics Market to 2017, Top Five Countries of Europe, Annual Cost of Treatment, $, 2010-2017
Table 21: Men’s Health Therapeutics Market to 2017, Top Five Countries of Europe, Treatment Usage Patterns, million, 2002-2010
Table 22: Men’s Health Therapeutics Market to 2017, Top Five Countries of Europe, Treatment Usage Patterns, million, 2010-2017
Table 23: Men’s Health Therapeutics Market to 2017, Japan, Revenue, $m, 2002-2010
Table 24: Men’s Health Therapeutics Market to 2017, Japan, Revenue Forecasts, $m, 2010-2017
Table 25: Men’s Health Therapeutics Market to 2017, Japan, Annual Cost of Treatment, $, 2002-2010
Table 26: Men’s Health Therapeutics Market to 2017, Japan, Annual Cost of Treatment, $, 2010-2017
Table 27: Men’s Health Therapeutics Market to 2017, Japan, Treatment Usage Patterns, million, 2002-2010
Table 28: Men’s Health Therapeutics Market to 2017, Japan, Treatment Usage Patterns, million, 2010-2017
Table 29: Erectile Dysfunction Therapeutics Market, Global, Revenue, $m, 2002-2010
Table 30: Erectile Dysfunction Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017
Table 31: Erectile Dysfunction Therapeutics Market, Global, Revenue Analysis by Country, $m, 2002-2010
Table 32: Erectile Dysfunction Therapeutics Market, Global, Revenue Analysis by Country, $m, 2010-2017
Table 33: Erectile Dysfunction Therapeutics Market, Global, Annual Cost of Treatment, $, 2002-2010
Table 34: Erectile Dysfunction Therapeutics Market, Global, Annual Cost of Treatment, $, 2010-2017
Table 35: Erectile Dysfunction Therapeutics Market, Global, Treatment Usage Patterns, million, 2002-2010
Table 36: Erectile Dysfunction Therapeutics Market, Global, Treatment Usage Patterns, million, 2010-2017
Table 37: Male Hypogonadism Therapeutics Market, Global, Revenue, $m, 2002-2010
Table 38: Male Hypogonadism Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017
Table 39: Male Hypogonadism Therapeutics Market, Global, Revenue Analysis by Country, $m, 2002-2010
Table 40: Male Hypogonadism Therapeutics Market, Global, Revenue Analysis by Country, $m, 2010-2017
Table 41: Male Hypogonadism Therapeutics Market, Global, Annual Cost of Treatment, $, 2002-2010
Table 42: Male Hypogonadism Therapeutics Market, Global, Annual Cost of Treatment, $, 2010-2017
Table 43: Male Hypogonadism Therapeutics Market, Global, Treatment Usage Patterns, (‘000), 2002-2010
Table 44: Male Hypogonadism Therapeutics Market, Global, Treatment Usage Patterns, (‘000), 2010-2017
Table 45: Premature Ejaculation Therapeutics Market, Global, Revenue, $m, 2002-2010
Table 46: Premature Ejaculation Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017
Table 47: Premature Ejaculation Therapeutics Market, Global, Revenue by Country ,$m, 2002-2010
Table 48: Premature Ejaculation Therapeutics Market, Global, Revenue by Country, $m, 2010-2017
Table 49: Premature Ejaculation Therapeutics Market, Global, Annual Cost of Treatment , $, 2002-2010
Table 50: Premature Ejaculation Therapeutics Market, Global, Annual Cost of Treatment, $, 2010-2017
Table 51: Premature Ejaculation Therapeutics Market, Global, Treatment Usage Patterns, million, 2002-2010
Table 52: Premature Ejaculation Therapeutics Market, Global, Treatment Usage Patterns, million, 2010-2017
Table 53: BPH Therapeutics Market, Global, Revenue, $bn, 2002-2010
Table 54: BPH Therapeutics Market, Global, Revenue Forecasts, $bn, 2010-2017
Table 55: BPH Therapeutics Market, Global, Revenue Analysis by Country, $m, 2002-2010
Table 56: BPH Therapeutics Market, Global, Revenue Analysis by Country, $m, 2010-2017
Table 57: BPH Therapeutics Market, Global, Annual Cost of Treatment, $, 2002-2010
Table 58: BPH Therapeutics Market, Global, Annual Cost of Treatment, $, 2010-2017
Table 59: BPH Therapeutics Market, Global, Treatment Usage Patterns (million), 2002-2010
Table 60: BPH Therapeutics Market, Global, Treatment Usage Patterns (million), 2010-2017
Table 61: Men’s Health Therapeutics Market to 2017, Global, R&D Pipeline by Indication, (%), 2011
Table 62: Men’s Health Therapeutics Market to 2017, Global, R&D Pipeline by Phase, (%), 2011
Table 63: Men’s Health Therapeutics Market to 2017, Global, R&D Pipeline by Phase in Erectile Dysfunction Market, (%), 2011
Table 64: Erectile Dysfunction Therapeutics Market, Global, Discovery Pipeline Molecules, 2011
Table 65: Erectile Dysfunction Therapeutics Market, Global, Preclinical/IND Filed Pipeline Molecules, 2011
Table 66: Erectile Dysfunction Therapeutics Market, Global, Phase I Pipeline Molecules, 2011
Table 67: Erectile Dysfunction Therapeutics Market, Global, Phase II Pipeline Molecules, 2011
Table 68: Erectile Dysfunction Therapeutics Market, Global, Phase III Pipeline Molecules, 2011
Table 69: Erectile Dysfunction Therapeutics Market, Global, NDA Filed Molecules, 2011
Table 70: Men’s Health Therapeutics Market to 2017, Global, R&D Pipeline by Phase in the Premature Ejaculation Market, (%), 2011
Table 71: Premature Ejaculation Therapeutics Market. Global, Discovery Pipeline Molecules, 2011
Table 72: Premature Ejaculation Therapeutics Market. Global, Preclinical Pipeline Molecules, 2011
Table 73: Premature Ejaculation Therapeutics Market. Global, Phase I Pipeline Molecules, 2011
Table 74: Premature Ejaculation Therapeutics Market. Global, Phase II Pipeline Molecules, 2011
Table 75: Premature Ejaculation Therapeutics Market. Global, Phase III Pipeline Molecules, 2011
Table 76: Men’s Health Therapeutics Market to 2017, Global, R&D Pipeline by Phase in Male Hypogonadism, (%), 2011
Table 77: Male Hypogonadism Therapeutics Market, Global, Preclinical Pipeline Molecules, 2011
Table 78: Male Hypogonadism Therapeutics Market, Global, Phase I Pipeline Molecules, 2011
Table 79: Male Hypogonadism Therapeutics Market, Global, Phase II Pipeline Molecules, 2011
Table 80: Male Hypogonadism Therapeutics Market, Global, NDA Filed Pipeline Molecules, 2011
Table 81: Men’s Health Therapeutics Market to 2017, Global, R&D Pipeline by Phase in Benign Prostatic Hyperplasia, (%), 2011
Table 82: Benign Prostatic Hyperplasia Therapeutics Market, Global, Preclinical Pipeline Molecules, 2011
Table 83: Benign Prostatic Hyperplasia Market, Global, Phase I Pipeline Molecules, 2011
Table 84: Benign Prostatic Hyperplasia Market, Global, Phase II Pipeline Molecules, 2011
Table 85: Benign Prostatic Hyperplasia Market, Global, Phase III Pipeline Molecules, 2011
Table 86: Benign Prostatic Hyperplasia Market, Global, NDA Filed Pipeline Molecules, 2011
Table 87: Men’s Health Therapeutics Market to 2017, Eli Lilly and Company, Men’s Health Pipeline, 2010
Table 88: Men’s Health Therapeutics Market to 2017, GlaxoSmithKline, Inc., Men’s Health Pipeline, 2010
Table 89: Men’s Health Therapeutics Market to 2017, Abbott Laboratories, Men’s Health Pipeline, 2010
Table 90: Men’s Health Therapeutics Market to 2017, Endo Pharmaceuticals Holding Inc, Men’s Health Pipeline, 2010
Table 91: Men’s Health Therapeutics Market to 2017, Bayer Healthcare AG, Men’s Health Pipeline, 2010
Table 92: Men’s Health Therapeutics Market to 2017, VIVUS Inc., Men’s Health Pipeline, 2010
Table 93: Men’s Health Therapeutics Market to 2017, Global, Deals by Type, 2004-2011
Table 94: Men’s Health Therapeutics Market to 2017, Global, M&A Deals by Value, (%), 2004-2011
Table 95: Men’s Health Therapeutics Market to 2017, Global, M&A Deals by Geography, (%), 2004- 2011
Table 96: Men’s Health Therapeutics Market to 2017, Global, Number of M&A Deals by Year, 2004-2011
Table 97: Men’s Health Therapeutics Market to 2017, Global, Major M&A Deals, 2007-2011
Table 98: Men’s Health Therapeutics Market to 2017, Global, Major Licensing Agreements By Geography (%), 2004-2011
Table 99: Men’s Health Therapeutics Market to 2017, Global, Major Licensing Agreements By Value, ($m), (%), 2004-2011
Table 100: Men’s Health Therapeutics Market to 2017, Global, Number of Licensing Deals by Year, 2004-2011
Table 101: Men’ Health Therapeutics Market to 2017, Major Licensing Agreements, 2009-2010
Table 102: Men’s Health Therapeutics Market to 2017, Global, Major Co-Development Deals, 2004-2006

List of Chart


Figure 1: Men’s Health Therapeutics Market to 2017, Global, Revenue Forecasts ,$m, 2002-2017
Figure 2: Men’s Health Therapeutics Market to 2017, Global, Generic/Off-label Share, %, 2010, 2017
Figure 3: Men’s Health Therapeutics Market to 2017, Global, Annual Cost of Treatment, $, 2002-2017
Figure 4: Men’s Health Therapeutics Market to 2017, Global, Treatment Usage Patterns, million, 2002-2017
Figure 5: Men’s Health Therapeutics Market to 2017, Global, Diseased Population, million, 2002-2017
Figure 6: Men’s Health Therapeutics Market to 2017, Global, Treatment Seeking Population, million, 2002-2017
Figure 7: Men’s Health Therapeutics Market to 2017, Global, Diagnosed Population, million, 2002-2017
Figure 8: Men’s Health Therapeutics Market to 2017, Global, Treated Population, million, 2002-2017
Figure 9: Men’s Health Therapeutics Market to 2017, Global, Market Drivers and Restraints
Figure 10: Men’s Health Market to 2017, Revenue Analysis by Country, $m, 2002-2017
Figure 11: Men’s Health Therapeutics Market to 2017, The US, Revenue Forecasts ,$m, 2002-2017
Figure 12: Men’s Health Therapeutics Market to 2017, The US, Annual Cost of Treatment ,$, 2002-2017
Figure 13: Men’s Health Therapeutics Market to 2017, The US, Treatment Usage Patterns, million, 2002-2017
Figure 14: Men’s Health Therapeutics Market to 2017, Top Five Countries of Europe, Revenue Forecasts, $m, 2002-2017
Figure 15: Men’s Health Therapeutics Market to 2017, Top Five Countries of Europe, Revenue Analysis by Country, $m, 2002-2017
Figure 16: Men’s Health Therapeutics Market to 2017, Top Five Countries of Europe, Annual Cost of Treatment, $, 2002-2017
Figure 17: Men’s Health Therapeutics Market to 2017, Top Five Countries of Europe, Treatment Usage Patterns, million, 2002-2017
Figure 18: Men’s Health Therapeutics Market to 2017, Japan, Revenue Forecasts, $m, 2002-2017
Figure 19: Men’s Health Therapeutics Market to 2017, Japan, Annual Cost of Treatment, $, 2002-2017
Figure 20: Men’s Health Therapeutics Market to 2017, Japan, Treatment Usage Patterns, million, 2002-2017
Figure 21: Erectile Dysfunction Therapeutics Market, Global, Revenue Forecasts, $m, 2002-2017
Figure 22: Erectile Dysfunction Therapeutics Market, Global, Revenue Analysis by Country, $m, 2002-2017
Figure 23: Erectile Dysfunction Therapeutics Market, Global Generic/Off-Label Share, (%), 2010, 2017
Figure 24: Erectile Dysfunction Therapeutics Market, Global, Annual Cost of Treatment, $, 2002-2017
Figure 25: Erectile Dysfunction Therapeutics Market, Global, Treatment Flow Algorithm for Erectile Dysfunction, 2011
Figure 26: Erectile Dysfunction Therapeutics Market, Global, Treatment Usage Patterns, million, 2002-2017
Figure 27: Male Hypogonadism Therapeutics Market, Global, Revenue Forecasts, $m, 2002-2017
Figure 28: Male Hypogonadism Therapeutics Market, Global, Revenue Analysis by Country, $m, 2002-2017
Figure 29: Male Hypogonadism Therapeutics Market, Global, Global Generic/Off-Label Share, $m, 2010, 2017
Figure 30: Male Hypogonadism Therapeutics Market, Global, Annual Cost of Treatment, $, 2002-2017
Figure 31: Male Hypogonadism Therapeutics Market, Global, Treatment Flow Algorithm for Male Hypogonadism, 2011
Figure 32: Male Hypogonadism Therapeutics Market, Global, Treatment Usage Patterns, (‘000), 2002-2017
Figure 33: Male Hypogonadism Therapeutics Market to 2017, Global, Prescription Share Analysis, (%), 2010
Figure 34: Premature Ejaculation Therapeutics Market, Global, Revenue Forecasts, $m, 2002-2017
Figure 35: Premature Ejaculation Therapeutics Market, Global, Revenue by Country, $m, 2002-2017
Figure 36: Premature Ejaculation Therapeutics Market, Global Generic Share, $m, 2010- 2017
Figure 37: Premature Ejaculation Therapeutics Market, Global, Annual Cost of Treatment, $, 2002-2017
Figure 38: Premature Ejaculation Therapeutics Market, Global, Treatment Flow Algorithm for Premature Ejaculation
Figure 39: Premature Ejaculation Therapeutics Market, Global, Treatment Usage Patterns, (‘000), 2002-2017
Figure 40: BPH Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017
Figure 41: BPH Therapeutics Market, Global, Revenue Analysis by Country, $m, 2002-2017
Figure 42: BPH Therapeutics Market, Global Generics/Off-Label Share, %, 2010, 2017
Figure 43: BPH Therapeutics Market, Global, Annual Cost of Treatment, $, 2002-2017
Figure 44: BPH Therapeutics Market, Global, Treatment Flow Algorithm for BPH, 2011
Figure 45: BPH Therapeutics Market, Global, Treatment Usage Patterns (million), 2002-2017
Figure 46: Men’s Health Therapeutics Market to 2017, Global, R&D Pipeline by Indication, (%), 2011
Figure 47: Men’s Health Therapeutics Market to 2017, Global, R&D Pipeline by Phase, (%), 2011
Figure 48: Men’s Health Therapeutics Market to 2017, Global, R&D Pipeline by Phase in Erectile Dysfunction Market, (%), 2011
Figure 49: Men’s Health Therapeutics Market to 2017, Global, R&D Pipeline by Phase in the Premature Ejaculation Market, (%), 2011
Figure 50: Men’s Health Therapeutics Market to 2017, Global, R&D Pipeline by Phase in Male Hypogonadism, (%), 2011
Figure 51: Men’s Health Therapeutics Market to 2017, Global, R&D Pipeline by Phase in Benign Prostatic Hyperplasia, (%), 2011
Figure 52: Men’s Health Therapeutics Market to 2017, Pfizer Inc., SWOT Analysis, 2011
Figure 53: Men’s Health Therapeutics Market to 2017, Eli Lilly and Company, SWOT Analysis, 2010
Figure 54: Men’s Health Therapeutics Market to 2017, GlaxoSmithKline, Inc, SWOT Analysis, 2010
Figure 55: Men’s Health Therapeutics Market to 2017, Abbott Laboratories, SWOT Analysis, 2010
Figure 56: Men’s Health Therapeutics Market to 2017, Endo Pharmaceuticals Holding Inc, SWOT Analysis, 2010
Figure 57: Men’s Health Therapeutics Market to 2017, Bayer Healthcare AG, SWOT Analysis, 2010
Figure 58: Men’s Health Therapeutics Market to 2017, Johnson & Johnson, SWOT Analysis, 2010
Figure 59: Men’s Health Therapeutics Market to 2017, VIVUS Inc., SWOT Analysis, 2010
Figure 60: Men’s Health Therapeutics Market to 2017, Auxilium Pharmaceuticals, Inc, SWOT Analysis, 2010
Figure 61: Men’s Health Therapeutics Market to 2017, Global, Deals by Type, (%), 2004-2011
Figure 62: Men’s Health Therapeutics Market to 2017, Global, M&A Deals by Value, (%), 2004-2011
Figure 63: Men’s Health Therapeutics Market to 2017, Global, M&A Deals by Geography, (%), 2004- 2011
Figure 64: Men’s Health Therapeutics Market to 2017, Global, Number of M&A Deals by Year, 2004-2011
Figure 65: Men’s Health Therapeutics Market to 2017, Global, Major Licensing Agreements By Geography, (%), 2004-2011
Figure 66: Men’s Health Therapeutics Market to 2017, Global, Major Licensing Agreements By Value, $m, (%), 2004-2011
Figure 67: Men’s Health Therapeutics Market to 2017, Global, Number of Licensing Deals by Year, 2004-2011
Figure 68: GBI Research Market Forecasting Model

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *